It's also interesting that right near the end, Yuman suggests that the trial patients have been through so many lines of treatment / chemo that their immune systems aren't quite up to the job, so the addition of a CAR T may be a point of difference.
I read into that both: expect oncarlytics to be better and expect that earlier treatment of healthier patients to be more effective.
Media Thread, page-15707
-
- There are more pages in this discussion • 360 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $334.7M | |||
| Open | High | Low | Value | Volume |
| 4.6¢ | 4.6¢ | 4.4¢ | $417.0K | 9.281M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 37 | 6074903 | 4.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.5¢ | 362283 | 5 |
View Market Depth
| Last trade - 16.10pm 07/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |